New combo therapy aims to boost immune attack on eye cancer
NCT ID NCT07203391
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 35 times
Summary
This early-stage trial tests whether adding a new drug called roginolisib to the existing treatment tebentafusp can help people with advanced uveal melanoma, a rare eye cancer. The study involves 8 adults whose cancer has spread and who are already on tebentafusp. The main goal is to find a safe dose and see if the combination helps the immune system stay active longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA, METASTATIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Alfred Hospital
NOT_YET_RECRUITINGMelbourne, Victoria, Australia
Contact
-
St Vincents Hospital
RECRUITINGSydney, New South Wales, 2010, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tebentafusp and roginolisib
What this could lead to
If this combination works, it could offer a new treatment option for advanced uveal melanoma by helping the immune system fight the cancer longer.
What could go wrong
This is a very early Phase 1 trial with only 8 participants, so it is primarily testing safety and dosing. The combination may not be effective or could cause significant side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.